On November 12, 2020 Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic,reported the additional funding of $10 million to advance its current pipeline of products as well as expand with additional in-licensed technologies (Press release, Bridge Medicines, NOV 12, 2020, View Source [SID1234570848]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bridge Medicines, launched in 2016 by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management Company and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute.
Bridge Medicines is currently developing novel inhibitors of ENL-YEATS for the treatment of acute leukemias such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. In addition, Bridge Medicines is in discussions on and evaluating several other in-licensing opportunities from our institutional partners.
"Bridge Medicines was founded four years ago on a mission to discover and develop promising therapeutic technologies emerging from the cutting-edge science discovered on the campuses of our renowned academic partners," said Bill Polvino, MD, Chief Executive Officer of Bridge Medicines. "We are privileged and pleased to benefit from the continued strong support of our investor partners who have provided financial and strategic support for our efforts from day one. Without the commitment of capital, and industry-savvy executives, the opportunity to develop highly innovative products is lost. Our partners share in our passion to meet the challenge of addressing unmet medical needs and creating a vibrant New York City biotech ecosystem."